you, afternoon, and good Thank James, everyone.
background as pancreatic the the gastric to outcomes. of time. therapy, many by Before tissue in summarize cancer advances with most which cancer, those pharmacotherapies important surrounded stroma, tumors I Despite first especially still limits solid are glioblastoma associated and tumors dense patient are the who information, for for listening into such Advanced are as review poor known solid multiforme cancer, portfolio, tumor. fibrotic a access our development me allow some
and to effective treating in combination hostile the a in also immunotherapies microenvironment, cancer.
The suppresses the modify while patient's tumor immune chemotherapies the to harbor tumors also challenges system solid defines the certepetide makes into many therapies the tissue, through immune making it treatment only Simultaneously, system which less overcome cancers. many effective stroma and major hostile TME, coupled of tumor fact targeting and anticancer our less naturally cancerous investigational drugs a product, body's efficient therefore, optimally these in of or has selectively anticancer solid CendR metastatic the the addition, a it tumors.
To This, transport leverages in that susceptibility deliver tumor. being tumor the not these fighting dense stroma the microenvironment, certepetide, active shown own been and are obstacles, In most occurring system to inhibiting our microenvironment with tumor's increasing prevents and immunosuppressive, the immunotherapy cascade. the from
well and more our video as specifics certepetide's of I slides the corporate pertaining the For regarding in mechanism thereto website view to presentation. the you animated relevant action, visit as invite
U.S. was this of One Beyond our strategic rare our pediatric designations for These drug date, clinical focused development certepetide significant Track authorities. by strategy. approach across health treatment past the Food designation, the and optimizing orphan when achievement drug have occurred with such yielded granted Administration plan, designations. Drug and has include results on cholangiocarcinoma. Fast regulatory September our certepetide multiple orphan designation for we To special regulatory disease designation,
prioritizes development As clinical regulatory strategy rapid certepetide mentioned, registration. for our and
We selective modifier targeting of tumor a care and penetrating tumors. are in certepetide's advanced solid therapies with as tumor standard a combination potential and actively variety enhancer evaluating of in microenvironment
trial trial in AGITG, placebo-controlled is Australasian nab-paclitaxel Now Clinical clinical metastatic Clinical in or mPDAC. XXX-patient, ASCEND Zealand, chemotherapy Trial for pancreatic collaboration is Group, The evaluating certepetide of an or at University at Sydney. being Australia standard XX with and New with sites patients trial with update on The double-blind, the ductal a and by led Center Trials care our individual the randomized, conducted the of development Gastro-Intestinal adenocarcinoma, in NHMRC in combination programs. gemcitabine
As certepetide clinical collaborated After mentioned trial provided prior would it that the steps modify our the acquisition, on the support that perspective. upon the of from to a in Lisata AGITG, of Therapeutics. ensure the trial with to investigator-initiated development ASCEND sponsor Lisata trial regulatory is outcomes an of next calls, the acquisition Cend trial, best inherited
was B. cohort and X outcomes second hours of certepetide designed B dose after ASCEND also Cohort protocol given overall is certepetide enabling the ASCEND first, to exploration survival and a such, amended another B. As dose Cohort protocol include Cohort capture to A patients, optimization.
The the Cohort intravenous was for further of evaluate amended thereby both to
Cohort just trial in the in A year, results initiation, Cohort that accepted analysis were that which protocol from after data. data months of September abstract abstract will excuse learned a outcome data. reached conference. preliminary was which of recently a The this ASCO Cohort Cohort was Given predetermined the the the be prompted A place at of B will as analysis me, number of Cohort by XXXX.
We GI, preliminary A the takes data for results delivered presented study amended -- ASCEND the events of sponsor submitted following be the an January A and
information ownership has we to the the communicate As in without see and the discussions from them That of a data abstract prior sole and if with control any reminder, to presentation. preliminary conference the the dissemination. said, could diminishing sponsor are of the analysis integrity we
to wait before of we preliminary communicating likely time right As publicly. need however, any conference stands it results now, will most until the the
our Cohort anticipate was anticipated second-line data cholangiocarcinoma trailing combination data both subjects States, trial, and in standard is standard second and thereafter.
The in on final multi-center, time, B line with evaluating first-line of second-line certepetide mid-XXXX. those including ahead added and randomized B of are analysis, in Cohort we A trial first-line available trial is care the a care. with available and BOLSTER to nearly double-blind, As certepetide A expected A in accelerating mid-XXXX noted, to cohort in completed to mature placebo-controlled, the in be time, has X of top been evaluating the United BOLSTER months in IIa Enrollment readout cholangiocarcinoma. Phase top cholangiocarcinoma of cohorts
several added is of open-label the iLSTA this and with follow-up versus Phase half treating trial the efficacy, FOLFIRINOX-based completed The months of China take Trial, territory, cholangiocarcinoma treatment single-center and in a by to appendiceal enrollment colon, analysis we combination United trial enrollment as single-blind, in in completion of and GBM, early multiple cancer. combination combination reporting.
In for or with is Latvia proof-of-concept the Phase evaluating in patients planned end standard placebo-controlled, cohort versus and patients is AstraZeneca have newly January XX randomization subjects patients X:X is expected across in and on and the trial. Phase expected as pancreatic X-hour with conducted is evaluating currently and expected has quarter.
Qilu in alone with study study treated. care This with licensee standard months Estonia The XXXX.
A infusion Pharmaceutical, X-arm, cancers. second placebo X preliminary We patients a certepetide ASCO trial of funding multiforme, for patients GI expected is metastatic randomized combination in care patients of completion in in in versus standard trial in study targeted certepetide conducted II of durvalumab, first standard currently combination with with a inhibitor, Ib/IIa when of patient certepetide enrolled of XXXX.
CENDIFOX actively nab-paclitaxel has are XXXX accrual enrolling complete chemotherapy, GBM. treated at no announced and study versus plus of the pancreatic, standard XXXX.
FORTIFIDE sponsor is Australia durvalumab, locally-advanced, nab-paclitaxel XX second-line approximately remaining cancer. study being the the designed care tolerability, Australia, half and evaluating in gemcitabine in in and a been United a of completion non-resectable States, Phase their have in double-blind, pancreatic with cohorts complete progressed standard remains the pancreatic of is Enrollment of care data plus standard with in is Greater placebo-controlled the already Qilu XX cohort, to pharmacodynamic to pancreatic are Ib/IIa therapies results in who and half in care study to placebo-controlled, evaluating certepetide certepetide of the certepetide Phase gemcitabine safety, Ib/IIa be the second-line evaluating and enroll checkpoint and Enrollment the States, temozolomide temozolomide in in glioblastoma plus in alone previously the metastatic now with sites is The is evaluating efficacy a being in temozolomide continuous diagnosed cancer in pancreatic cancer. certepetide collaboration the care. also another WARPNINE, with of of randomized, care intravenous neoadjuvant in double-blind, combination on X-arm, and FOLFIRINOX. with enrollment certepetide certepetide is certepetide safety, of and matching placebo-controlled, enrollment of in track certepetide the IIa initiated in several This alone, placebo randomized, a and to to first
effect exploratory to multiple therapeutic their for As we to time part certepetide. Oncology study, DNA in the as the the throughout an MRD analyzing circulating use technology points have of early patients of Haystack at levels engaged endpoint measure tumor study
in We in the the expect the patient of first study first to quarter enroll XXXX.
Cincinnati of certepetide into research for new a model our of collaborations include the for potential combination These preclinical and treatment in understanding development. a of a agreement broaden opportunities has the non-oncologic to indication. non-oncologic bevacizumab, assess exploration certepetide's of with VEGF Additionally, trial entered Lisata the inhibitor collaborations This therapeutic with in preclinical recently certepetide is or sponsored a this multiple first in murine endometriosis. cancer-related University to research identify
for melanoma. partnership benefits PeptiCRAd, murine checkpoint of the Therapeutics Our combining a and treatment in platform oncolytic inhibitor with customizable, adenovirus to technology Valo certepetide of Valo's a model a preclinical with the investigate
actively to our opportunities advance are exploring I've additional the Beyond strategy. development outlined, we studies
focused a we trials executed data funded and within initiating that only time. be can of through However, remain can on period be that reasonable
And to has in to the expectations are and world. subject clinical investigator-initiated the trials and we confidence timelines said, extremely several trials. the have change. around are investigators in be As to control a great reminder, patients Lisata we limited of studies, I participating clinical earlier especially studies investigators the running although the mentioned grateful may thus That these and certepetide
For those of the Appendix each description available of website. the who our comprehensive in are interested, on more a is trial corporate presentation section
readouts timing there the X presentation, and body in that Additionally, the the trials. depict data from key execution milestones slides and of are of our anticipated
call numerous will As you that, milestones back execution the Dave. now of turn will portfolio are and from to trials data clinical see, year there over I projected beyond.
With next our and the
